Vimarsana
Biggest News Aggregation in the World

Page 2 - Diverse Models News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Diverse Models. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Diverse Models Today - Breaking & Trending Today

IHG continues to lead booming business travel market in greater china with diversified investment initiatives : Tuesday, 23rd May 2023 : 4Hoteliers - Vimarsana News

IHG continues to lead booming business travel market in greater china with diversified investment initiatives : Tuesday, 23rd May 2023 : 4Hoteliers

With the continuous recovery of domestic tourism in China, the demand for business and MICE travel has surged.Responding

IHG continues to lead booming business travel market in greater china with diversified investment initiatives - Vimarsana News

IHG continues to lead booming business travel market in greater china with diversified investment initiatives

With the continuous recovery of domestic tourism in China, the demand for business and MICE travel has surged. Responding to this market growth, IHG Hotels & Resorts launched its 2023 IHG Greater China Expo & Owner Roadshow with the theme of "Go Beyond", hosting events in Shenzhen, Shanghai, and Beijing to showcase the company’s robust development in the business travel market.

'Your diversity doesn't count': Levi's AI models prompt anger, but the denimwear label says they're not a substitute for real action - Vimarsana News

'Your diversity doesn't count': Levi's AI models prompt anger, but the denimwear label says they're not a substitute for real action

Levi’s has been criticised for using AI as a replacement for hiring diverse models, but the denimwear label says it does not regard AI models as a substitute for real action on diversity.

Source: scmp.com
Janssen EMEA Receives Conditional Marketing Authorisation for RYBREVANT ? (amivantamab), the First Treatment Approved for Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations... - Vimarsana News

Janssen EMEA Receives Conditional Marketing Authorisation for RYBREVANT ? (amivantamab), the First Treatment Approved for Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations...

For EU Trade and Medical Media Only. Not to Be Distributed to UK and Benelux Based Media Conditional Marketing Authorisation is based on results from the Phase 1 CHRYSALIS study evaluating amivantamab

Janssen Receives Positive CHMP Opinion for RYBREVANT (amivantamab) for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations After Failure of Platinum-Based Therapy - Vimarsana News

Janssen Receives Positive CHMP Opinion for RYBREVANT (amivantamab) for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations After Failure of Platinum-Based Therapy

If approved by the European Commission, amivantamab will be the first treatment in the European Union specifically targeting EGFR exon 20 insertion mutations for advanced non-small cell lung cancer